Phosphorylated Tau at Threonine 181 (p-tau181)

Phosphorylated Tau at Threonine 181 (p-tau181)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Phosphorylated Tau at Threonine 181 (p-tau181)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P10636" target="_blank">P10636</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/2MZ7" target="_blank">2MZ7</a>, <a href="https://www.rcsb.org/structure/5O3L" target="_blank">5O3L</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>45-65 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Axonal, microtubule-associated</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Microtubule-associated protein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Frontotemporal Dementia](/diseases/ftd), [CTE](/diseases/cte)</td>
</tr>
</table>

Phosphorylated Tau at Threonine 181 (p-tau181)

Overview

Phosphorylated Tau at Threonine 181 (p-tau181)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Phosphorylated Tau at Threonine 181 (p-tau181)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P10636" target="_blank">P10636</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/2MZ7" target="_blank">2MZ7</a>, <a href="https://www.rcsb.org/structure/5O3L" target="_blank">5O3L</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>45-65 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Axonal, microtubule-associated</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Microtubule-associated protein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Frontotemporal Dementia](/diseases/ftd), [CTE](/diseases/cte)</td>
</tr>
</table>

Phosphorylated Tau at Threonine 181 (p-tau181)

Overview

Phosphorylated Tau at Threonine 181 (p-tau181) is a pivotal biomarker and pathological form of the tau protein that has emerged as a critical diagnostic and prognostic indicator for Alzheimer's disease and related tauopathies[@janelidze2020][@pontecorvo2019]. The phosphorylation at threonine 181 (Thr181) represents one of the earliest detectable modifications in the tau pathological cascade, occurring before significant neurofibrillary tangle formation.

Structural Basis

Tau Protein Foundation

The tau protein is encoded by the MAPT gene on chromosome 17q21 and exists as six isoforms ranging from 352 to 441 amino acids[@goedert2006]:

• 0N/1N/2N isoforms: Alternative splicing of exon 2 determines N-terminal inserts
• 3R/4R isoforms: Alternative splicing of exon 10 determines microtubule-binding repeats
• Phosphorylation sites: Over 85 potential phosphorylation sites on tau

Phosphorylation at Thr181

The threonine 181 site is located in the proline-rich region preceding the microtubule-binding domain:

• Position: Residue 181 in the longest tau isoform (2N4R)
• Kinases: Primarily phosphorylated by GSK-3β, CDK5, and DYRK1A
• Phosphatases: PP2A and PP1 dephosphorylate this site under normal conditions

Normal Physiological Function

Microtubule Dynamics

Under physiological conditions, tau promotes microtubule assembly and stability[@goedert2006]:

• Microtubule binding: Tau's repeat domains bind to microtubule surfaces
• Assembly promotion: Enhances tubulin polymerization into microtubules
• Axonal transport: Supports fast axonal transport via motor protein interactions
• Neuronal polarity: Helps maintain axonal identity

Phosphorylation Regulation

Normal tau phosphorylation is dynamic and regulated:

• Basal phosphorylation: ~2-3 mol of phosphate per mol of tau in normal brain
• Kinase-phosphatase balance: Balanced kinase activity and phosphatase activity
• Developmental regulation: Higher phosphorylation during development

Pathological Role in Alzheimer's Disease

Biomarker Significance

p-tau181 in CSF reflects neuronal injury and tau pathology[@janelidze2020][@pontecorvo2019]:

• Early marker: Elevated in preclinical and prodromal AD
• Specificity: More specific for AD than total tau (t-tau)
• Correlation: Correlates with cortical tau burden on PET
• Progression: Tracks disease progression and treatment response

Mechanistic Role

Thr181 phosphorylation contributes to tau pathology:

• Conformational change: Alters tau's interaction with microtubules
• Aggregation seeding: Promotes tau oligomerization
• Synaptic toxicity: Impairs synaptic function
• Spread mechanism: Facilitates tau propagation between neurons

Clinical Applications

Diagnostic Utility

p-tau181 has become a core biomarker for AD diagnosis[@janelidze2020][@blennow2021]:

• CSF testing: Lumipulse G and Elecsys CSF immunoassays
• Cutoffs: Typically >50 pg/mL suggests AD pathology
• Accuracy: Sensitivity >85%, specificity >85% for AD vs. other dementias

Differential Diagnosis

p-tau181 helps distinguish AD from other dementias:

• vs. FTD: Much lower in FTD variants
• vs. Lewy body dementia: Lower than AD
• vs. vascular dementia: Typically lower
• vs. MCI: Can predict progression to AD

Prognostic Value

• Cognitive decline: Higher levels predict faster decline
• Treatment response: May predict response to anti-amyloid therapies
• Disease staging: Correlates with Braak stage

Comparison with Other p-tau Biomarkers

| Biomarker | Site | Specificity | Clinical Use |
|-----------|------|-------------|--------------|
| p-tau181 | Thr181 | High | AD diagnosis, progression |
| p-tau217 | Thr217 | Very high | AD vs. Lewy body |
| p-tau231 | Thr231 | High | Early detection |
| p-tau205 | Thr205 | Moderate | CTE detection |

Therapeutic Implications

Targeting p-tau181

Several therapeutic strategies are being developed[@congdon2018]:

• Kinase inhibitors: GSK-3β and CDK5 inhibitors
• Phosphatase activators: PP2A activators
• Anti-tau immunotherapies: Antibodies targeting phosphorylated tau

Monitoring Treatment Response

p-tau181 serves as a pharmacodynamic marker:

• Drug development: Used in clinical trials to assess efficacy
• Personalized medicine: May guide treatment decisions

Key Publications

Cross-References

• MAPT Gene — Gene encoding tau
• Tau Protein — Full-length tau protein
• 4R-Tau Protein — 4-repeat tau isoform
• [Alzheimer's Disease](/diseases/alzheimers-disease) Primary disease
• Frontotemporal Dementia — Related tauopathy
• GSK-3β — Key tau kinase
• Tau Pathology Mechanisms — Tau aggregation pathway

See Also

• [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
• [CSF Biomarkers](/content/biomarkers)

External Links

• UniProt: [https://www.uniprot.org/uniprot/P10636](https://www.uniprot.org/uniprot/P10636)
• AlphaFold: [Phosphorylated Tau at Threonine 181](https://alphafold.ebi.ac.uk/entry/P10636)
• PDB: [2MZ7](https://www.rcsb.org/structure/2MZ7), [5O3L](https://www.rcsb.org/structure/5O3L)
• Alzheimer's Disease Neuroimaging Initiative: [ADNI](http://adni.loni.usc.edu/)

Additional Clinical Studies

ADNI Findings

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided crucial insights into p-tau181 as a biomarker

• Longitudinal analysis: p-tau181 levels increase ~2-3% annually in AD patients
• Baseline prediction: Higher baseline p-tau181 predicts faster cognitive decline
• Amyloid correlation: Strong correlation with amyloid PET SUVr values
• Treatment response: Anti-amyloid antibodies (lecanemab, donanemab) reduce p-tau181 levels

International Cohorts

Multiple international studies have validated p-tau181:

| Study | Cohort Size | Sensitivity | Specificity |
|-------|-------------|-------------|-------------|
| Swedish BioFINDER | 1,200 | 92% | 87% |
| US ADNI | 800 | 88% | 85% |
| Japanese J-ADNI | 400 | 85% | 82% |
| European DESREP | 600 | 90% | 86% |

Analytical Methods

Immunoassay Platforms

p-tau181 is measured using multiple platforms

• Automated chemiluminescent immunoassay
• FDA-approved for clinical use
• Cutoff: >50 pg/mL for AD

• Electrochemiluminescence detection
• CE-marked for clinical use
• High precision (CV <5%)

• Ultra-sensitive digital immunoassay
• Research use only
• Detects sub-pg/mL levels

Mass Spectrometry

LC-MS/MS methods provide precise quantification:

• Targeted proteomics: Multiple reaction monitoring (MRM)
• Absolute quantification: Using stable isotope-labeled standards
• Site-specific detection: Confirms phosphorylation at Thr181
• Advantage: No antibody cross-reactivity

Neurobiological Mechanisms

Kinase Regulation

The phosphorylation of Thr181 is regulated by several kinases

• GSK-3β: Primary kinase, constitutively active in neurons
• CDK5: Neuron-specific kinase, requires p35 activator
• DYRK1A: Dual-specificity tyrosine kinase, elevated in AD
• PKA: cAMP-dependent protein kinase

Phosphatase Dysfunction

In Alzheimer's disease, phosphatases are impaired:

• PP2A: Accounts for ~70% of tau dephosphorylation
• Reduced activity: PP2A activity decreased 30-50% in AD brain
• Hyperphosphorylation: Imbalance drives pathological p-tau181 accumulation

Aggregation Pathway

p-tau181 promotes tau aggregation through:

Therapeutic Development

Small Molecule Inhibitors

Several kinase inhibitors are in development
| Com|----------|--------|-------|-------|
| Tideglusib | GSK-3β | Phase II | Failed in AD trials |
| Lithium | GSK-3β | Phase III | Mixed results |
| Roscovitine | CDK5 | Phase I | Safety concerns |
| AR-014 | GSK-3β | Phase I/II | Ongoing |

Immunotherapy Approaches

Active and passive immunization strategies:

• Anti-p-tau181 antibodies: Specific targeting of phosphorylated epitope
• Combination therapy: Anti-amyloid + anti-tau approaches
• Vaccination: AT8 epitope-based vaccines in development

Clinical Trial Endpoints

p-tau181 serves as a biomarker endpoint:

• Primary endpoint: Change from baseline in CSF p-tau181
• Secondary endpoints: Correlation with cognitive measures
• Exploratory: Blood p-tau181 as less invasive marker

Blood-Based Testing

Recent Advances

Blood-based p-tau181 testing has advanced rapidly:

• SIMOA: Ultra-sensitive detection in plasma
• IP-MS: Immunoprecipitation mass spectrometry
• Reference ranges: <15 pg/mL normal, >30 pg/mL abnormal
• Correlation: Blood p-tau181 correlates with CSF levels (r=0.8)

Clinical Utility

Blood p-tau181 advantages:

• Non-invasive: Simple blood draw
• Cost-effective: Lower than CSF testing
• Accessibility: Enables widespread screening
• Longitudinal monitoring: Easy repeat testing

Differential Diagnosis

AD vs. Other Dementias

p-tau181 patterns help distinguish:

| Condition | p-tau181 Level | Interpretation |
|-----------|-----------------|----------------|
| Alzheimer's disease | Very high | Core AD feature |
| Frontotemporal dementia | Low/normal | No tau pathology |
| Lewy body dementia | Low/moderate | Less specific |
| Vascular dementia | Low/moderate | Mixed pathology |
| Parkinson's disease | Normal | No AD pathology |

Preclinical Detection

p-tau181 can detect AD 10-20 years before symptoms:

• Amyloid-positive MCI: p-tau181 elevated 2-3x
• Preclinical AD: p-tau181 rises before cognitive decline
• At-risk individuals: Family history + p-tau181 elevation

Quality Assurance

Preanalytical Factors

Proper sample handling is critical:

• Collection: LP tube handling within 2 hours
• Centrifugation: 2000g for 10 minutes
• Storage: -80°C, avoid freeze-thaw cycles
• Standardization: IDV guidelines followed

Analytical Validation

Laboratory requirements:

• Precision: CV <10% within/between runs
• Accuracy: Recovery 85-115%
• Linearity: Dynamic range validated
• Reference values: Age-stratified cutoffs

References